Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2025-12-25 @ 2:32 AM
NCT ID:
NCT03480334
Eligibility Criteria:
Inclusion Criteria:
* Progression of refractory or relapsed cHL during treatment with an anti-PD1 agent
* At least two distinct FDG-avid HL-lesions with at least 5 cm distance between them, and one of them considered eligible for irradiation with 20Gy based on localization and prior RT exposure
* Age at registration ≥ 18 years
Exclusion Criteria:
* Nodular-lymphocyte predominant HL (NLPHL) or composite/greyzone lymphoma
* Lymphoma involving the central nervous system
* Naïve to treatment with anti-PD1 targeting antibodies
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03480334
Study Brief:
Protocol Section:
NCT03480334